{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:29:53Z","timestamp":1775798993955,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.bbmt.2019.10.031","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T12:24:31Z","timestamp":1572956671000},"page":"351-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"26","author":[{"given":"Fei-Fei","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Fei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2019.10.031_bib0001","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","article-title":"The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China\u2014recommendations from the Chinese Society of Hematology","volume":"11","author":"Xu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0002","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0003","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1158\/1078-0432.CCR-15-2335","article-title":"Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0004","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/leu.2016.110","article-title":"Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant","volume":"30","author":"Wang","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0005","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.bbmt.2016.01.006","article-title":"Haploidentical hematopoietic stem cell transplantation: a global overview comparing Asia, the European Union, and the United States","volume":"22","author":"Apperley","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0006","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/bmt.2014.19","article-title":"Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers","volume":"49","author":"Chang","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0007","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJM199906033402202","article-title":"Transplantation of anergic histoincompatible bone marrow allografts","volume":"340","author":"Guinan","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0008","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0009","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.2007.06533.x","article-title":"Management of acute graft-versus-host disease","volume":"137","author":"Bacigalupo","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0010","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0011","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/bbmt.2002.v8.pm12171485","article-title":"Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0012","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.V76.8.1464.1464","article-title":"A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment","volume":"76","author":"Martin","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0013","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1182\/blood-2006-12-041889","article-title":"How I treat refractory acute GVHD","volume":"109","author":"Deeg","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0014","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbmt.2011.06.012","article-title":"Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment","volume":"18","author":"Xhaard","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0015","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.bbmt.2019.07.017","article-title":"Outcomes and predictors of response in steroid-refractory acute graft-versus-host disease","volume":"25","author":"Rashidi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0016","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbmt.2017.03.029","article-title":"Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients","volume":"23","author":"Khandelwal","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0017","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.25376","article-title":"Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: clinical and immunological results","volume":"94","author":"Gonzalez Vicent","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0018","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.bbmt.2018.11.017","article-title":"Etanercept as treatment of steroid-refractory acute graft-versus-host disease in pediatric patients","volume":"25","author":"Faraci","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0019","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bmt.1705761","article-title":"Infliximab for GVHD therapy in children","volume":"40","author":"Sleight","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0020","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/petr.12183","article-title":"The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients","volume":"18","author":"Khandelwal","year":"2014","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0021","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.bbmt.2016.09.016","article-title":"A prospective study of alemtuzumab as a second-line agent for steroid-refractory acute graft-versus-host disease in pediatric and young adult allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Khandelwal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0022","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/petr.12545","article-title":"Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation","volume":"19","author":"Inagaki","year":"2015","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0023","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2141.2005.05631.x","article-title":"Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease","volume":"130","author":"Schmidt-Hieber","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0024","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/sj.bmt.1703737","article-title":"Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation","volume":"30","author":"Massenkeil","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0025","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.transproceed.2011.03.044","article-title":"Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched\/haploidentical hematopoietic stem cell transplantation","volume":"43","author":"Wang","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0026","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.bmt.1705306","article-title":"Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist","volume":"37","author":"Funke","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0027","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ejh.12691","article-title":"Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody","volume":"97","author":"Chakupurakal","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0028","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/cncr.20613","article-title":"Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management","volume":"101","author":"Couriel","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0029","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/bjh.15672","article-title":"Hepatitis E virus infection after haploidentical haematopoietic stem cell transplantation: incidence and clinical course","volume":"184","author":"Tang","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jcv.2017.07.018","article-title":"Risk factors for herpes simplex virus-1\/2 viremia and clinical outcomes following unmanipulated haploidentical haematopoietic stem cell transplantation","volume":"95","author":"Tang","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0031","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjh.14225","article-title":"Haploidentical transplantation for acquired severe aplastic anaemia in a multicentre prospective study","volume":"175","author":"Xu","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0032","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2018.08.030","article-title":"The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0033","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0034","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.10.031_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ctr.13146","article-title":"Utility of flexible bronchoscopy with polymerase chain reaction in the diagnosis and management of pulmonary infiltrates in allogeneic HSCT patients","volume":"32","author":"Tang","year":"2018","journal-title":"Clin Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911930713X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911930713X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:09:04Z","timestamp":1761059344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911930713X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S108387911930713X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.10.031","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}